http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115068602-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2022-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115068602-B |
| titleOfInvention | A composite vaccine adjuvant of surface-modified alumina, preparation method and application |
| abstract | The present application relates to the technical field of alumina vaccine adjuvants, in particular to a composite vaccine adjuvant of surface-modified alumina, a preparation method and an application. The preparation method comprises: mixing alumina and polysaccharide in a mixture containing benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium chloride, tetrabutylammonium hydrogen sulfate, trioctylmethylammonium chloride The composite vaccine adjuvant of the surface-modified alumina is prepared by reacting at least one of dodecyltrimethylammonium chloride and tetradecyltrimethylammonium chloride in an alcoholic solution. The compound vaccine adjuvant can mediate the vaccine adjuvant for obtaining Th1 and/or Th2 immune response, so as to be suitable for vaccination against diseases such as intracellular infection, viral infection or cancer. |
| priorityDate | 2022-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 154.